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Glutamate and GABA in autism spectrum
disorder—a translational magnetic
resonance spectroscopy study in man and
rodent models
Jamie Horder1, Marija M. Petrinovic2,7, Maria A. Mendez1, Andreas Bruns2, Toru Takumi3, Will Spooren2,
Gareth J. Barker 4, Basil Künnecke2 and Declan G. Murphy1,5,6
Abstract
Autism spectrum disorder (ASD) is a pervasive neurodevelopmental syndrome with a high human and economic
burden. The pathophysiology of ASD is largely unclear, thus hampering development of pharmacological treatments
for the core symptoms of the disorder. Abnormalities in glutamate and GABA signaling have been hypothesized to
underlie ASD symptoms, and may form a therapeutic target, but it is not known whether these abnormalities are
recapitulated in humans with ASD, as well as in rodent models of the disorder. We used translational proton magnetic
resonance spectroscopy ([1H]MRS) to compare glutamate and GABA levels in adult humans with ASD and in a panel of
six diverse rodent ASD models, encompassing genetic and environmental etiologies. [1H]MRS was performed in the
striatum and the medial prefrontal cortex, of the humans, mice, and rats in order to allow for direct cross-species
comparisons in speciﬁc cortical and subcortical brain regions implicated in ASD. In humans with ASD, glutamate
concentration was reduced in the striatum and this was correlated with the severity of social symptoms. GABA levels
were not altered in either brain region. The reduction in striatal glutamate was recapitulated in mice prenatally
exposed to valproate, and in mice and rats carrying Nlgn3 mutations, but not in rodent ASD models with other
etiologies. Our ﬁndings suggest that glutamate/GABA abnormalities in the corticostriatal circuitry may be a key
pathological mechanism in ASD; and may be linked to alterations in the neuroligin–neurexin signaling complex.
Introduction
Autism spectrum disorder (ASD) is a pervasive neuro-
developmental syndrome characterized by deﬁcits in
social reciprocity and communication, and by restricted
interests and repetitive behaviors (DSM-5)1. ASD affects
1–2% of the population and is up to ﬁve times more
common in males than in females2. The high-societal
burden of ASD is exacerbated by the fact that there are no
effective pharmacological treatments for the core symp-
toms of the disorder. This is principally because the
etiology and pathophysiology of ASD are largely unclear,
thus leading to a lack of therapeutic targets. Most ASD
cases are idiopathic, i.e., they cannot be ascribed to any
known etiological cause3, and while genetic and envir-
onmental risk factors accounting for some cases of ASD
have been identiﬁed, the neural mechanisms involved
remain uncertain.
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However, emerging evidence suggests that
abnormalities in the balance between excitatory (gluta-
mate-mediated), and inhibitory (GABA-mediated)
neurotransmission may be a common pathophysiological
mechanism and hence a treatment target in ASD4–6. For
instance, abnormalities in the expression of glutamate and
GABA receptors have been observed in the postmortem
brains of people with ASD7. In vivo, proton magnetic
resonance spectroscopy ([1H]MRS) has revealed altera-
tions in the levels of glutamate and glutamine in the
cortex and basal ganglia of children, and in the basal
ganglia in adults with ASD8–16. Moreover, reductions in
GABA have been reported in several brain regions in
children with ASD13,17–20. While these studies are con-
sistent with and support the hypothesis of an excitation/
inhibition (E/I) imbalance in ASD, their respective ﬁnd-
ings do not always concur in terms of the directionality of
the imbalance, and the underlying biological mechanism
(s) remain poorly understood7–20. Progress can be made,
however, with the help of rodent models of ASD. These
models encompass diverse etiologies including genetic,
chromosomal, i.e., copy number variations (CNVs), and
environmental insults21. This offers a powerful toolbox to
explore the underpinnings of an E/I imbalance in ASD.
Electrophysiological and biochemical investigations in
animal models of ASD have revealed brain region- and
model-speciﬁc imbalances in E/I function6,22–26, yet it has
been difﬁcult to relate these ﬁndings to human ASD due
to the invasive nature of the techniques, e.g., brain slice
recordings, that are typically used. In contrast, [1H]MRS
is noninvasive and can be safely used in humans and in
animals alike—thus allowing direct inter-species com-
parisons. Yet, comparable [1H]MRS investigations of
glutamate and GABA in both humans and rodent models
of ASD do not currently exist.
Therefore, in order to determine whether ASD is
associated with abnormal levels of glutamate and GABA
in vivo, and to explore its putative biological under-
pinnings, we conducted a translational [1H]MRS study in
both humans with idiopathic ASD and a panel of rodent
models of ASD. We selected six etiologically diverse
models to cover a wide range of previously identiﬁed risk
factors for non-syndromic ASD in humans, namely (1)
prenatal exposure to valproate (valproic acid, VPA), an
environmental risk factor for ASD27, (2) paternal dupli-
cation of the 15q11-13 chromosomal region, the most
frequent ASD-associated CNV28–31, and (3) three mono-
genic models carrying mutations in synapse-related genes
that have been linked with ASD in humans: Shank3
knockout (KO) mice26,32, and Nlgn3R451C knock-in (KI)
mice and Nlgn3 KO rats, both of which with mutations in
the same gene, thus permitting comparisons across two
rodent species25,33. In addition, an inbred mouse strain,
the BTBR T+tf/J mice34, with strong face validity but
unknown genetics was used as a model of ASD of pre-
sumed polygenic origin. We performed [1H]MRS in the
same brain regions across humans, mice, and rats in order
to allow for direct cross-species comparisons. We chose
to focus on two brain areas previously implicated in both
ASD pathology and social behavior in individuals without
ASD, namely the striatum and the medial prefrontal
cortex (mPFC)6,11,35–37.
Materials and methods
Human participants
A total of 25 individuals with idiopathic ASD were
recruited from the Behavioral Genetics Clinic at the
Maudsley Hospital, a national referral service for the
diagnosis of neurodevelopmental disorders. Control par-
ticipants were recruited via local advertisements. Inclu-
sion criteria for all human participants included: (1) full-
scale IQ of ≥80; (2) not currently taking any psychoactive
medication and no psychoactive medication within at
least the past six weeks; (3) no history of epilepsy, head
injury, brain disease or infection, or serious medical illness
(by self-report); (4) no history of bipolar disorder, schi-
zophrenia, or drug or alcohol dependency; (5) no con-
traindications for MRI scanning i.e., no metallic implants,
pacemakers, or history of major surgery to the head or
chest. Participants in the ASD group were required to
meet International Classiﬁcation of Disease-Revision 10
(ICD-10) research criteria for autism. All diagnoses were
conﬁrmed using the Autism Diagnostic Observation
Schedule (ADOS-G) and where possible also with the
Autism Diagnostic Interview-Revised. A summary of the
recruited participants’ demographics is given in Table 1.
The two groups did not differ in age, gender, or in either
full-scale IQ, verbal IQ or performance IQ as assessed
using the Wechsler Abbreviated Scale of Intelligence.
Ethical approval for this study was provided by the Essex 2
National Research Ethics Committee (reference 04-
Q0102/26). Full written informed consent according to
the Declaration of Helsinki was obtained from all
participants.
Human [1H]MRS: data acquisition and processing
The striatum (including the head of the caudate, the
anterior putamen, and the internal capsule) and the mPFC
were selected as regions-of-interest (ROI) on the grounds
that neuropathological and MRI studies have linked these
brain areas to ASD6,11,35–37 and that we showed a
reduction in Glx (combined pools of glutamate, gluta-
mine, and glutathione) in striatum previously11. As
practical considerations limited us to a single unilateral
striatal ROI, we chose the left striatum in order to
maintain maximum compatibility with our former
study11. Moreover, earlier studies reported independency
of metabolite levels with the ROI laterality38–40. For the
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cortical ROI, the bilateral mPFC including the cingulate
gyrus was selected. Supplementary Figure 1a depicts
examples of ROI placements.
[1H]MRS data were acquired on a 3T GE HDxt MRI
scanner (GE Medical Systems, Milwaukee, WI, USA). A
structural MRI scan for subsequent ROI positioning and
tissue segmentation was acquired using a 3D fast
inversion-recovery prepared gradient echo acquisition
(inversion time (TI)= 450ms, repetition time (TR)=
7ms, echo time (TE)= 2.8 ms, matrix= 256 × 256 × 124
with a 0.9375 × 0.9375 × 1.1 mm3 voxel size). [1H]MRS
spectra were acquired using Meshcher–Garwood Point-
Resolved Spectroscopy (MEGAPRESS). MEGAPRESS is a
widely used spectral editing technique that allows the
quantiﬁcation of GABA in humans at magnetic ﬁeld
strengths in which GABA is not readily detectable using
plain point-resolved spectroscopy (PRESS) alone41. Exci-
tation and refocusing pulses were shifted 2 ppm upﬁeld
from water, such that the voxel’s position was correct for
metabolites lying in the center of the spectrum, and to
minimize chemical shift displacements in the volume
selection for the metabolite range of interest. Glutamate
and glutamine were estimated from the “unedited”
MEGAPRESS spectra (which is equivalent to a PRESS
spectrum), as in the “edited” spectra coediting with GABA
occurs42. GABA was quantiﬁed from the “difference”
(edited–unedited) spectra. One ROI (35 × 30 × 25mm)
was placed in the left striatum. A second ROI (25 × 40 ×
30mm) was placed on the mPFC. Acquisition parameters
were: TR= 2000ms, TE= 68 ms and a total of 368
averages per ROI: 176 edit-on, 176 edit-off, and 16 with
unsuppressed water for water scaling. [1H]MRS spectra
were processed using LCModel software (version 6.3-0I;
http://s-provencher.com/lcmodel.shtml). Water scaling
was performed by LCModel, i.e., each metabolite peak
was normalized by expressing its magnitude as a ratio
against the magnitude of the unsuppressed water peak.
Water-scaled estimates were comparable across ROIs and
across participants and are expressed in institutional units
as described previously11. Spectra were visually inspected,
and LCModel quality control parameters were reviewed
to verify that spectra were not qualitatively abnormal: all
signal-to-noise ratios were ≥14 (striatum: 20.70 ± 3.35;
mPFC: 21.10 ± 3.76) and all full widths at half maximums
were ≤0.11 ppm (striatum: 0.07 ± 0.015 ppm; mPFC: 0.05
± 0.022 ppm). Poorly ﬁtted spectra with Cramer–Rao
lower bounds equal to or higher than 20% of the meta-
bolic estimate for either glutamate, glutamine or GABA,
were excluded from further analysis; this led to the
exclusion of one Glx and one GABA estimate from the
mPFC ROI of a participant in the control group. The
quality of acquired [1H]MRS spectra is shown in Sup-
plementary Figure 1b-d.
To control for interindividual differences in ROI tissue
composition, a scaling procedure was used, as previously
described11. In brief, the structural MRI was ﬁrst
segmented into gray matter (GM), white matter (WM),
and cerebrospinal ﬂuid (CSF) using Statistical Parametric
Mapping software (SPM2; http://spm.ion.ucl.ac.uk).
For each spectroscopy ROI, its position was registered
to the segmented structural images and the GM,
WM, and CSF content of the ROI was calculated using in-
house software. Absolute metabolite values were then
calculated from the raw water-scaled LCModel (version
6.3-0I; http://s-provencher.com/lcmodel.shtml) outputs
as follows:
Metababsolute ¼ Metabraw
´ ðGM þWM þ 1:55 ´CSFð Þ=GM þWMÞ
where GM, WM, and CSF together sum up to 1. The
(1.55 × CSF) term is included because CSF contains more
water than GM or WM, and thus CSF tends to lower
water-scaled estimates of the metabolites, in addition to
the usual partial volume effects11. In the striatum, the
groups did not differ on mean tissue contribution of GM,
WM, or CSF as indicated by independent-samples
unpaired two-tailed t-tests (all p-values >0.44) (controls:
GM 52.5%, WM 43.3%, CSF 8.4%; ASD: GM 52.4%, WM
Table 1 Summary of demographic and clinical
characteristics of human participants
Clinical
characteristics
Controls n= 36
(mean ± SEM)
ASD n= 25
(mean ±
SEM)
ASD vs.
controls
p-value
Age (years) 28.91 ± 1.40 30.98 ± 1.81 0.36
Verbal IQ 117.29 ± 1.91 115.05 ± 3.31 0.53
Performance IQ 115.32 ± 2.26 114.32 ± 3.74 0.81
Full-scale IQ 118.66 ± 4.07 114.23 ± 3.19 0.23
ADI-R social
interaction
NA 16.11 ± 1.26 NA
ADI-R
communication
NA 12.58 ± 1.56 NA
ADI-R repetitive
behavior
NA 4.74 ± 0.56 NA
ADOS-G social
interaction
NA 7.73 ± 0.46 NA
ADOS-G
communication
NA 4.00 ± 0.36 NA
The control group did not receive ADI-R or ADOS-G assessment. For reference,
the widely accepted cut-offs for ASD diagnosis are: ADI-R: ≥10 (social
interaction), ≥8 (communication), ≥3 (repetitive behavior); ADOS-G: ≥4 (social
interaction), ≥2 (communication), ≥7 (social interaction and communication
combined). Data are depicted as mean ± SEM; two-tailed t-test
ADI-R Autism Diagnostic Interview-Revised, ADOS-G Autism Diagnostic Observa-
tion Schedule, ASD autism spectrum disorder, IQ intelligence quotient, NA not
applicable
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43.8%, and CSF 8.0%). In the mPFC, there was a sig-
niﬁcant group difference in GM contribution, which was
higher in the ASD group (controls: 57.0%; ASD: 58.7%; p
= 0.01; two-tailed t-test). The GM increase possibly
reﬂects altered cortical neuroanatomy in the ASD
group43. As brain structure is not the focus of the present
study, however, we did not attempt to further characterize
this difference but instead entered GM contribution
percentage as a covariate in the group comparisons in
the mPFC. No differences were seen in WM (controls:
25.8%; ASD: 24.3%; p= 0.19; two-tailed t-test) or CSF
contribution (controls: 20.6%; ASD: 20.3%; p= 0.70; two-
tailed t-test).
Rodent models
[1H]MRS investigations were carried out in ﬁve mouse
models and one rat model of ASD. Mouse models
included: mice prenatally exposed to VPA and age-
matched saline-exposed controls (Harlan Laboratories,
Horst, Netherlands; CD1 background), BTBR T+tf/J mice
(The Jackson Laboratory, Bar Harbor, ME, USA) and age-
matched wild-type C57BL/6J controls (The Jackson
Laboratory, Bar Harbor, ME, USA), 15q11-13 patDP mice
(kindly provided by T. Takumi, RIKEN, Wako, Japan;
C57BL/6J genetic background), Shank3 KO mice (The
Jackson Laboratory, Bar Harbor, ME, USA; C57BL/6J
genetic background), Nlgn3R451C KI mice (The Rock-
efeller University, NY, USA; C57BL/6J genetic back-
ground), and respective wild-type littermates. In addition,
Nlgn3 KO rats and their wild-type littermates (Horizon
Discovery, Boyertown, PA, USA; Sprague-Dawley genetic
background) were used. An overview of rodent models
and their behavioral characteristics is given in Table 2. A
total of 75 ASD-like animals and corresponding 73 con-
trols were investigated in groups of 7–15 animals per
condition (Table 2). The targeted sample size of ideally
≥12 animals per condition was based on previous in-
house variability assessments44 and had to be reduced for
logistical reasons in some cases. The animals were
selected randomly from different litters. All animals were
male adults aged 12–16 weeks (rodent equivalent of the
age range of human study-participants)45 and weighing,
depending on species and strain, 20–50 g (mice) and
350–500 g (rats) at the time of the study. Animals were
group-housed (two to three per cage) in a temperature-,
humidity-, and light-controlled environment (22–24 °C,
40–60%, 12 h light/dark cycle) and had access to food and
water ad libitum. Animal experiments were approved
by the Federal Food Safety and Veterinary Ofﬁce
of Switzerland (references BS-2359 and BS-2523)
and conducted in strict adherence to the Swiss federal
ordinance on animal protection and welfare, as well
as according to the rules of the Association for
Assessment and Accreditation of Laboratory Animal Care
International.
Rodent [1H]MRS: data acquisition and processing
[1H]MRS in rodents was performed on a Biospec 9.4T/
20 cm horizontal bore small animal MR scanner (Bruker,
Ettlingen, Germany), equipped with an actively decoupled
two-coil system consisting of a resonator for signal exci-
tation, and a head surface coil for reception. For [1H]
MRS, mice were initially anesthetized with 2.5–3% iso-
ﬂurane (Abbott, Baar, Switzerland) in carrier gas com-
posed of oxygen and air (1:5 v/v) supplied with a face
mask to the freely breathing animal. Subsequently, eto-
midate (Etomidate-®Lipuro; B. Braun Melsungen AG,
Melsungen, Germany) was administered as a primed
continuous intravenous infusion according to the proce-
dures and conditions reported previously45. Rats were
anesthetized with isoﬂurane only: isoﬂurane concentra-
tion was adjusted between 2.0 and 2.3% to maintain stable
respiratory rates of 60 breaths/min. Animals were placed
in a custom-made cradle and their heads were immobi-
lized in a stereotaxic frame. Respiratory rate, rectal body
temperature, and CO2 level in the exhaled air were con-
tinuously monitored throughout the experiment as pre-
viously described46,47. Body temperature was maintained
Table 2 Summary of etiological and behavioral characteristics of rodent models of ASD
Rodent models and their controls n Social behavior Communication Repetitive behavior Reference
VPA- vs. saline-treated mice 8+ 7 Impaired Altered USVs Increased 27
BTBR T+tf/J vs. C57Bl/6J WT mice 15+ 15 Impaired Altered USVs Increased 34
15q11-13 patDp vs. WT mice 10+ 10 Impaired Altered USVs No change 28–31
Shank3 KO vs. WT mice 15+ 15 Impaired Altered USVs Increased 26,32
Nlgn3R451C KI vs. WT mice 15+ 14 Impaired Altered USVs No change 25
Nlgn3 KO vs. WT rats 12+ 12 Impaired Altered USVs Increased 33
All the mouse models were on a C57BL/6J background, except for VPA (CD1) and BTBR T+tf/J mice. The rat model was on a Sprague-Dawley background. Wild-type
littermates were used as controls, except for VPA and BTBR T+tf/J mice for which age-matched saline-treated CD1 and wild-type C57BL/6J mice served as respective
controls
ASD autism spectrum disorder, KI knock-in, KO knockout, patDp paternal duplication, USVs ultrasonic vocalizations, VPA valproic acid, WT wild type
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at 37 °C using a feedback-regulated electric heating
blanket.
Anatomical reference images were obtained by rapid
acquisition with refocused echoes (RARE)48 (TR=
1800 ms, TEeff= 36ms, RARE-factor 8, matrix 256 × 256
over 20 × 20 mm and 40 × 40 mm for mice and rats,
respectively). Two ROI homologous to those in humans
were selected in the right striatum and the mPFC. The
right striatum was chosen based on the purported lack of
metabolite lateralization and to ensure compatibility with
our previous studies44 and an extensive in-house database
of rodent [1H]MRS data. The ROIs encompassed ~6 µl in
mice (striatum: 2 × 1.8 × 1.8 mm; mPFC: 1.5 × 2.6 ×
1.5 mm) and ~16 µl in rats (striatum and mPFC: 2.5 ×
2.5 × 2.5 mm). Examples of ROI locations are shown in
Supplementary Figure 2a, b. Local magnetic ﬁeld homo-
geneity was adjusted for both ROIs separately by applying
Fastmap49. [1H]MRS was carried out by PRESS, as the
high magnetic ﬁeld of 9.4T allows direct detection of
GABA without using spectral editing techniques such as
MEGAPRESS50. Acquisition parameters were: TR=
2000 ms and TE= 10ms, 4 kHz spectral width sampled
with 2048 complex data points and 512 averages collected
over 17min. The PRESS sequence was modiﬁed such that
the frequencies of the excitation (1.35 ms hermite shape,
4 kHz bandwidth) and refocusing (1.2 ms hermite shape,
2.85 kHz bandwidth) pulses were shifted 2 ppm upﬁeld
from water such as to minimize chemical shift displace-
ments in the volume selection for the metabolite range of
interest. Water suppression was accomplished using a
series of variable power radio frequency pulses on the
water resonance51, interleaved with outer volume sup-
pression with adiabatic pulses (1 mm gaps to ROI, 5 mm
saturation slabs). An unsuppressed water spectrum was
obtained immediately preceding each acquisition of a
metabolite spectrum using identical acquisition para-
meters but only eight averages52. Quantitative analysis of
the [1H]MRS data were carried out using LCModel
software (version 6.3-0D) in a fully automated pipeline.
The basis set comprised model spectra for 17 metabolites
and eight macromolecular/lipid components. Absolute
metabolite concentrations were determined with refer-
ence to unsuppressed water, uncorrected for relaxation.
Spectral ﬁts were reviewed visually to verify that spectra
were qualitatively normal. The quality of acquired [1H]
MRS spectra is shown in Supplementary Figure 2a,b.
Predeﬁned exclusion criteria comprised poor signal-to-
noise ratio (ﬁve or lower) and head movement detected
during data acquisition. Furthermore, glutamine estimates
were excluded when they exceeded 3.5 mM (this value
representing our empirical in-house threshold separating
subjects with abnormally high-glutamine levels53 from
subjects with normal glutamine levels). Only the latter
criterion led to exclusion of data points, namely ten
glutamine estimates from mPFC and striatum of ﬁve
animals.
While there was no blinding with respect to the animals’
genotype/strain during data acquisition, processing, or
statistical analysis, the entire pipeline was fully automated,
and apart from visual inspection of the spectra there was
no step at risk of introducing user bias.
Statistical analyses
Mean metabolite concentrations were compared pair-
wise between individuals with ASD and controls using
two-tailed independent-samples t-tests with p < 0.05 as
the signiﬁcance criterion. The same approach was used to
compare the mean metabolite concentrations between the
animal model groups and their respective control groups.
Tests were performed independently for each group,
metabolite and ROI, yielding 44 comparisons (humans:
eight; animals: 36) for neurometabolites of primary
interest (glutamate, glutamine, Glx, and GABA) and 56
comparisons (humans: eight; animals: 48) for metabolites
of secondary interest (creatine, choline, N-acetylaspartate
+N-cetylaspartylglutamate (NAA+NAAG), and myo-
inositol). To account for these multiple comparisons, the
false discovery rate (FDR) was estimated within each of
these two priority levels, based on the p-value distribution
and its deviation from a uniform distribution, as pre-
viously described54,55. Comparisons between ASD cases
or animal model groups and their respective control
groups yielded 14 signiﬁcant differences of neuro-
transmitters and 11 signiﬁcant differences of further
metabolites of secondary interest. Expected FDR levels
were estimated to be 5% and 27%, respectively (i.e.,
expected numbers of false positives are around 1 and 3).
Especially for the metabolites of primary interest, this
number is reasonably low, while it seems acceptable for
the other metabolites, given that the latter are only meant
to provide auxiliary aspects of the disease endophenotype.
Residuals per group, metabolite, and ROIs were tested for
deviations from a normal distribution and for unequal
variances between the conditions compared (i.e., ASD
(model) vs. control). None of these tests passed FDR
control across conditions, indicating no evidence of vio-
lation of t-test assumptions.
For the human study, correlations among metabolite
concentrations and clinical measures were calculated
using Pearson’s product moment coefﬁcient. JMP 10 (SAS
Institute, Inc., Cary, NC, USA) and GraphPad Prism 6
(GraphPad Software Inc., La Jolla, CA, USA) software
were used for data analysis and preparation of graphs.
Results
[1H]MRS in individuals with ASD
In this cohort of adult males with idiopathic ASD (Table
1), we observed a signiﬁcant reduction of glutamate in the
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striatum as compared with healthy controls (Fig. 1a;
Supplementary Table 1). Glx (combined pools of gluta-
mate, glutamine and glutathione) was also decreased
(controls: 5.80 ± 0.25; ASD: 4.92 ± 0.35; p= 0.04; two-
tailed t-test; Supplementary Table 1). Yet, no differences
were seen in glutamine (Fig. 1c; Supplementary Table 1)
or in GABA (Fig. 1e; Supplementary Table 1) in this brain
region. In the mPFC, there was no difference in glutamate
(Fig. 1b; Supplementary Table 1), glutamine (Fig. 1d;
Supplementary Table 1), Glx (controls: 6.77 ± 0.14; ASD:
6.93 ± 0.16; p= 0.47; two-tailed t-test; Supplementary
Table 1), or GABA (Fig. 1f; Supplementary Table 1).
For the concomitantly detected cerebral metabolites
creatine, NAA+NAAG, and myo-inositol, no differences
were observed in either of the two brain regions (Sup-
plementary Table 2). Choline was increased in both
striatum and mPFC of people with ASD (Supplementary
Table 2).
As striatal glutamate and Glx differed between groups,
we examined whether these metabolite levels were cor-
related with current ASD symptom severity scores as
measured using the ADOS, the current “gold standard”
clinician-rated measure of core ASD behaviors. Striatal
glutamate and Glx were both signiﬁcantly, negatively
correlated with ADOS social impairments: ASD indivi-
duals with lower (more abnormal) glutamate and Glx
displayed worse social function (glutamate: r=−0.56, p
= 0.005; Glx: r=−0.63, p= 0.002; both signiﬁcant after
Bonferroni correction for two ROIs × two ADOS scales).
There was no correlation between striatal glutamate or
Glx and the severity of repetitive behaviors (glutamate: r
=−0.07, p= 0.77; Glx: r=−0.07, p= 0.77).
[1H]MRS in rodent models of ASD
In parallel to the human [1H]MRS studies, we evaluated
the neurochemical differences in six rodent models of
ASD with different underlying etiologies that emulate
the breadth of potential risk factors in idiopathic ASD
(Table 2). Across the models several neurochemical dif-
ferences were observed.
A decrease in striatal glutamate was the most consistent
ﬁnding, being observed in Nlgn3R451C KI mice, Nlgn3 KO
rats, and in mice prenatally exposed to VPA (Fig. 2a;
Supplementary Table 3). In Nlgn3R451C KI mice and Nlgn3
KO rats, a decrease in glutamate levels was also seen in
the mPFC (Fig. 2b; Supplementary Table 3).
Among the other models, different patterns of changes
were seen. For instance, glutamate and glutamine were
elevated in the striatum of BTBR T+tf/J mice (Fig. 2a, c;
Supplementary Table 3). Glutamine was elevated in the
striatum and mPFC of 15q11-13 paternal duplication
(patDp/+; henceforth referred to as 15q11-13 patDp)
mice, whereas reduced glutamine levels were observed in
the mPFC of Nlgn3R451C KI and Shank3 KO mice (Fig. 2d;
Fig. 1 Comparison of glutamate, glutamine and GABA levels
observed by [1H]MRS in striatum and mPFC of individuals with
ASD and control subjects. Left panels: striatal levels (in institutional
units) of a glutamate, c glutamine, and e GABA. Right panels: mPFC
levels (in institutional units) of b glutamate, d glutamine, and f GABA.
Data are depicted as mean ± SEM of n= 25–36 per group; *p < 0.05;
two-tailed t-test. This difference remains signiﬁcant with the removal
of the putative outlier in the control group, p= 0.037. ASD autism
spectrum disorder, i.u. institutional units, mPFC medial prefrontal
cortex. For additional data see Supplementary Table 1
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Supplementary Table 3). Our observation of no altera-
tions in GABA in humans with ASD was recapitulated in
most of the rodent models, including Nlgn3R451 KI mice,
Nlgn3 KO rats, and VPA mice (Fig. 2e, f; Supplementary
Table 3). Elevated GABA levels were observed only in the
striatum of BTBR T+tf/J mice (Fig. 2e; Supplementary
Table 3).
Several brain region- and model-speciﬁc changes were
also noted in other commonly reported neurometabolites
(Supplementary Table 4). Myo-inositol levels were altered
in the striatum and mPFC of Nlgn3 KO rats and BTBR
T+tf/J mice (Supplementary Table 4). In BTBR T+tf/J
mice, creatine was increased in the striatum but strongly
decreased in the mPFC (Supplementary Table 4). In
Fig. 2 Comparison of glutamate, glutamine and GABA concentrations observed by [1H]MRS in the striatum and mPFC of rodent models of
ASD and their corresponding controls. Left panels: concentrations (in mM) of a glutamate, c glutamine, and e GABA in striatum. Right panels:
concentrations (in mM) of b glutamate, d glutamine, and f GABA in mPFC. All the mouse models (colored bars) were on a C57BL/6J background,
except for VPA (CD1) and BTBR T+tf/J mice. The rat model (colored bars) was on a Sprague-Dawley background. Wild-type (gray bars) littermates
were used as controls, except for VPA and BTBR T+tf/J mice for which age-matched saline-treated CD1 and wild-type C57BL/6J mice served as
respective controls. Note the strain-dependent differences in glutamate levels. Data are depicted as mean ± SEM of n= 7–15 per group; *p < 0.05,
**p < 0.01, ***p < 0.001; two-tailed t-test. KI knock-in, KO knockout, mPFC medial prefrontal cortex, patDp paternal duplication, VPA valproic acid. For
additional data see Supplementary Table 2
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contrast, in Nlgn3 KO rats creatine was elevated in the
mPFC (Supplementary Table 4). Levels of NAA+NAAG
and choline-containing metabolites were only altered in
BTBR T+tf/J mice (Supplementary Table 4).
Discussion
In this translational [1H]MRS study, we examined glu-
tamate and GABA levels in people with ASD and in six
rodent models of the disorder. Consistent with the con-
cept of a glutamate/GABA imbalance in ASD, we found
that adults with idiopathic ASD have decreased glutamate
concentration in the striatum compared to controls. The
association between striatal glutamate and the severity of
social impairment implies that this abnormality is clini-
cally signiﬁcant. In contrast to our ﬁndings with gluta-
mate, we observed no alterations in GABA in adults with
ASD. Further, we showed that reduced striatal glutamate
is recapitulated in a subset of rodent models, namely in
mice exposed prenatally to valproate, and in both mice
and rats carrying mutations in the ASD-associated gene
Nlgn3 although in these models mPFC glutamate was also
reduced.
Our current human [1H]MRS results replicate and
extend our previous ﬁndings of reduced Glx in the
striatum, but not in the cortex, of people with ASD11. We
are now also able to conﬁrm that it is the excitatory
neurotransmitter glutamate that is reduced in the stria-
tum in ASD. This is because of the higher magnetic ﬁeld
strength of the 3T MRI scanner used in the present study
vs. 1.5T in our previous work11, which allows for the
separate quantiﬁcation of glutamate and glutamine, and
minor contributions of glutathione. The glutamate
reduction is regionally speciﬁc, however, which may
explain the differing ﬁndings of cortical glutamate across
various studies in which [1H]MRS was performed in dif-
ferent cortical areas8–16. Brain region- and even neural
circuit-speciﬁc changes in the E/I balance have also been
observed in animal models of ASD6,22–26.
In the present study, we did not observe differences in
GABA concentration in adults with ASD in either the
striatum or in the mPFC. However, reductions in GABA
have been observed in [1H]MRS studies of children with
ASD13,17–20. Therefore, GABA abnormalities in ASD
could be age-dependent. Future research should examine
GABA longitudinally over the life course—both in
humans and in rodent ASD models—in order to deter-
mine whether the maturational trajectory of the GABA
system is altered in ASD.
We assessed six rodent models of ASD as part of this
translational study, and showed that the abnormality seen
in individuals with ASD—namely a striatal glutamate
deﬁcit—was recapitulated in VPA-exposed mice,
Nlgn3R451C KI mice, and Nlgn3 KO rats. Our novel ﬁnding
is that these rodent models of ASD are similar to each
other with regard to this key neurochemical change, and
that they recapitulate the change seen in human idio-
pathic ASD, thus pointing to a common pathophysiology.
Literature on valproate and on Nlgn3 offers intriguing
clues that support this notion of a common pathophy-
siology. Valproate is an anticonvulsant and antimanic
agent with multiple direct pharmacological effects, such
as enhancing GABA neurotransmission56. VPA is also
known to modulate gene expression via inhibition of
histone deacetylase56, and in particular, VPA has been
shown to reduce expression of NLGN357, thus mimicking
the effect of the genetic manipulation in Nlgn3R451C KI
mice and Nlgn3 KO rats. Both point mutations58 and
deletions59,60 of this gene have been identiﬁed in people
with ASD, and are modeled by Nlgn3R451C KI mice and
Nlgn3 KO rats, respectively.
The mechanism by which mutations in the postsynaptic
cell-adhesion protein NLGN3 affects the striatal gluta-
mate system is unclear. Nevertheless, its involvement in
synapse function and the clustering of synaptic vesicles in
the presynaptic buttons25,26,61,62 suggests that NLGN3
deﬁciency may result in a decreased number of glutamate-
containing presynaptic vesicles. Unlike in humans with
ASD, Nlgn3 mutant mice and rats also showed reduced
glutamate in the mPFC, suggesting that the abnormalities
were less regionally speciﬁc perhaps due to the perva-
siveness of the genetic alterations in the brains of these
models.
We also observed a tendency toward reduction in
striatal glutamate and glutamine levels in the Shank3 KO
mice. SHANK3, like NLGN3, is a synaptic protein
implicated in ASD pathology26,63, and it also signals
through the neuroligin–neurexin complex64. This implies
both a pathophysiological convergence in SHANK3- and
NLGN3-deﬁcient rodents and a potential mechanism
underpinning the regionally speciﬁc neurochemical
abnormalities that we observed in humans.
Our ﬁnding of altered striatal glutamate might appear
surprising, given that the striatum is primarily composed
of GABAergic medium spiny neurons in which glutamate
levels are very low65,66. However, glutamate is contained
within glutamatergic inputs from the cerebral cortex, i.e.,
corticostriatal projections, in this region. Hence, the [1H]
MRS-observable reduction in striatal glutamate in both
people with ASD, and in particular animal models of the
disorder, might reﬂect the presence of fewer (or less
effective) corticostriatal projections. This interpretation is
in line with reports that individuals with ASD have
impaired long range connectivity67 and reduced neural
activity in corticostriatal circuits in response to a variety
of social rewards68,69. Thus our ﬁnding of a correlation
between striatal glutamate levels and the severity of social
deﬁcits is consistent with the role of striatum in social
behaviors36,37.
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We observed reduced striatal glutamate in humans with
ASD and more prevalently in several ASD rodent models.
Based on observations that the MRS-amenable glutamate
and GABA pools relate to neural function44, this result is
opposing the original hypothesis of neural excitability in
ASD put forward by Rubenstein and Merzenich5. This
hypothesis of increased excitation was largely based on
the observation that epilepsy frequently co-occurs with
ASD5. However, the majority of ASD individuals do not
have seizures70, and epilepsy is not simply a consequence
of an increase in neuronal excitation71. Moreover, work
on other animal models of ASD supports the idea of a
shift in the E/I balance away from excitation24.
Our study has some limitations. While [1H]MRS offers
the unique possibility of noninvasively measuring meta-
bolite concentration across species, a restriction of the
technique is that it measures the total concentration of
metabolites, e.g., glutamate, within a selected ROI and
cannot distinguish between synaptic, neuronal and glial
pools. However, for glutamate, there is indication that the
neurotransmitter and metabolic pools are correlated44,72,
and glial and extracellular glutamate pools are several-
folds smaller than the neuronal pool65,73,74. Therefore,
glutamate concentration measured by [1H]MRS can be
viewed as proportional to the neuronal neurotransmitter
pool.
Regarding the limitations of the human [1H]MRS study,
our sample size was modest. However, it was comparable
with, or larger than, similar studies8–20 and our key
ﬁnding of reduced striatal Glx in ASD replicates our
previous study in a new cohort of participants11. We
excluded subjects with a below-normal IQ or a history of
epilepsy or seizures. This was done in order to ensure that
our sample was broadly representative of the ASD
population, since the majority of ASD cases do not have
epilepsy70 and recent studies suggest that most have
normal range IQ75. Nonetheless, many individuals with
ASD do exhibit these features and therefore more
research would be required to conﬁrm whether our
results hold in such cases. A further limitation is that we
were unable to estimate true absolute concentrations in
the human [1H]MRS. The estimates we calculated are
comparable between individuals, but cannot be directly
interpreted as concentrations (in mM) because of a
number of assumptions made in the analysis of [1H]MRS
data in LCModel. For instance metabolite estimates vary
depending on how macromolecules are estimated and the
method we used (estimating eight macromolecule peaks)
has been scrutinized51. This, however, does not affect the
validity of our between-group comparisons because the
same analysis was used for all spectra.
A further, conceptual limitation is that our animal
models (except BTBR T+tf/J mice) are based on speciﬁc
etiological factors, and do not model idiopathic ASD as
such. However, there are no animal models of idiopathic
ASD in this sense, as even BTBR T+tf/J mice were
reported to share some genetic features with clinical
ASD76–78. Our hypothesis was that individuals with ASD
and rodent models of ASD may share key pathophysio-
logical mechanisms regardless of etiology79. In order to
identify possible points of convergence that would guide
future mechanistic investigations, we selected a range of
animal models, while restricting our selection to “non-
syndromic” ASD models as syndromic forms of ASD,
associated with gross neuroanatomical, and morphologi-
cal abnormalities, could represent unusual subtypes.
In the rodent study, our use of anesthesia to facilitate
in vivo [1H]MRS constitutes a difference from our human
studies, but the alternative of scanning awake animals,
would also have introduced bias due to stress experienced
by the rodents80. We have previously demonstrated
reliability of [1H]MRS in detecting changes in glutamate
and GABA in anesthetized animals44. We cannot com-
pletely exclude interactions of anesthesia with neuro-
transmitter levels, e.g., elicited by the anesthetics’ effect on
GABAA receptors
81. However, as we used the same
anesthetic regime for all the animal models and their
controls, it is unlikely that this could explain the differ-
ences in glutamate and GABA between rodent groups.
Cross-species matching by age (or developmental and
maturational stage) for a direct comparison of human and
rodent data is complex. Notwithstanding, mice aged
3–4 months, as used in this study, have been reported to
reﬂect a human equivalent of early adulthood45, thus
broadly reﬂecting the human cohorts. Also, we did not
perform [1H]MRS and behavioral assessments in the
same animals to avoid potential confounds related to the
series and sequence of experimental procedures. Previous
work has shown that behavioral testing could induce
changes in neurometabolite levels82. On the other hand,
the imaging procedure with 1H of anesthesia could
impact upon subsequent behavioral testing.
As practical considerations limited us to a single uni-
lateral striatal ROI, we chose the left striatum in humans
and the right striatum in our animal models in order to
maintain maximum compatibility with our former stu-
dies11,44 and extensive in-house databases. Earlier stu-
dies38–40, as well as our separate [1H]MRS study
performed in the left striatum of saline-treated C57BL/6J
and BTBR T+tf/J mice reported levels for glutamate
(C57BL/6J: 4.88 ± 0.08; BTBR T+tf/J: 5.61 ± 0.11), gluta-
mine (C57BL/6J: 2.52 ± 0.08; BTBR T+tf/J: 2.96 ± 0.08),
and GABA (C57BL/6J: 2.08 ± 0.05; BTBR T+tf/J: 2.42 ±
0.06) that closely mirrored those measured here in the
right striatum of those two mouse strains, thus suggesting
the absence of metabolite lateralization.
Finally, another technical difference between our
human and animal studies was the difference in [1H]MRS
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magnetic ﬁeld strength and pulse sequence used (3T
MEGAPRESS vs. 9.4T PRESS) along with ROI size dif-
ferences. However, both of these are methods optimized
and qualiﬁed for the two species, and there is no a priori
reason to expect them to differ in their ratiometric
measurements.
In conclusion, in this ﬁrst translational [1H]MRS study
in ASD, we replicated and extended our previous ﬁnding
that high-functioning adults with idiopathic ASD have
reduced glutamate in the striatum11, while we detected no
change in GABA. We further showed that the reduction
in striatal glutamate is related to core ASD symptom
severity. Moreover, reduction in striatal glutamate was
recapitulated in rodents carrying mutations in Nlgn3 or
being prenatally exposed to VPA. These translational
ﬁndings support the notion of glutamatergic dysfunction
in the corticostriatal pathway as an underlying core
pathophysiological mechanism of ASD. However, con-
trary to the original hypothesis put forward by Rubenstein
and Merzenich5 that ASD might be rooted in increased
cortical excitability, our data on humans, as well as ours
and recent work24 on several rodent models of ASD, are
suggestive of a region-speciﬁc imbalance slanted toward
reduced excitation.
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